Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Sildenafil (Revatio®) 10mg/ml powder for oral suspension is recommended as an option for use within NHS Wales for the treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease. |
|||
|
|||
Medicine details |
|||
| Medicine name | sildenafil citrate (Revatio®) | ||
| Formulation | 10 mg/ml powder for oral suspension | ||
| Reference number | 1675 | ||
| Indication | Treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease |
||
| Company | Pfizer Ltd | ||
| BNF chapter | Cardiovascular system | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 4012 | ||
| NMG meeting date | 07/11/2012 | ||
| AWMSG meeting date | 12/12/2012 | ||
| Ratification by Welsh Government | 16/01/2013 | ||
| Date of issue | 23/01/2013 | ||
| Date of last review | 30/09/2016 | ||